索米妥昔单抗注射液 | China Drugs ListMirvetuximab soravtansine injection | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

其他

商品名
Elahere
企业
ImmunoGen, Inc. / AbbVie
药品类型
生物药Biologic
治疗领域
肿瘤科Oncology
公开来源记录的适应症
美国说明书涵盖接受一至三种全身治疗方案后的成人叶酸受体α阳性、铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌。患者选择须采用经批准的叶酸受体α检测方法。The US label covers adults with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic treatment regimens. Patient selection requires an approved folate receptor alpha test.
适应症来源与口径
美国处方资料; 主要修订于 2025年7月. 部分境外适应症;不确立中国批准范围。US prescribing information; major change July 2025. Selected overseas indications; does not establish the Chinese approved scope.
说明书信息局限
已链接境外官方处方资料;尚未核实完整的现行中国说明书。Overseas official prescribing information linked; a complete current Chinese label has not been verified.
中国可获得性状态
本次英文来源核查未独立核实中国批准详情及当前供应情况。Chinese approval details and current availability have not been independently verified in this English-source review.
海外状态
请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异;尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
医保分类
尚未核实Not yet verified
医保版本
中国国家医保信息待核实Chinese national insurance review pending
医保核查说明
本次新增记录尚未确定报销资格;缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.

来源

证据核查日期:

打开交互详情、公开价格与讨论